We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Medical Device Combines Nanotechnology to Diagnose Kidney Disease

By LabMedica International staff writers
Posted on 17 Mar 2015
A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the one million people in the UK who don't know they have kidney disease. More...


Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.

The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.

The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.

Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”

Related Links:

Bio Nano Consulting 
Institution of Mechanical Engineers 



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.